AKT1 and acute myeloid leukemia: Together, these preclinical studies suggest that DNA repair and survival of AML cells mediated by therapy-induced activation of a DDR and its collateral enhancement of constitutive mutational PI3K/AKT activation represents a key resistance mechanism in AML patients treated with DNA damaging therapies.